LEAMINGTON SPA, England, Sept. 10, 2013 /PRNewswire/ -- Hospira (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced the European Commission (EC) ...

-- Subsequent entry biologic (SEB) medicine provides a lower-cost, high-quality, safe and effective therapy for rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — Researchers have observed a “modest uptake” in the use of biosimilars for infliximab in the past 18 ...

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved INFLECTRA™ (biosimilar infliximab) ...

-- Subsequent entry biologic (SEB) medicine provides a lower-cost, high-quality, safe and effective therapy for rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and ...

The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by ...

Please provide your email address to receive an email when new articles are posted on . Patients with inflammatory bowel disease who switched from Remicade to Inflectra showed no differences in drug ...

- The new independent clinical study data presented at EULAR's annual congress this week adds to the growing wealth of data for Hospira's Inflectra (infliximab), the first biosimilar monoclonal ...

inflectra-approved-RA-psoriasis-crohns-CA0416 The biosimilar has also been approved for Crohn's disease, ulcerative colitis, and ankylosing spondylitis. The FDA has approved the biosimilar Inflectra ...

The US Food and Drug Administration (FDA) today approved a biosimilar version of infliximab (Remicade, Janssen Biotech) called infliximab-dyyb (Inflectra, Janssen Biotech) that treats gastrointestinal ...

· Patients in the UK can finally benefit from the availability of Inflectra following the patent expiry of reference product Remicade ® (infliximab) · Inflectra provides an alternative, potentially ...

TORONTO, March 27, 2025--(BUSINESS WIRE)--Celltrion, Inc., a leading global biopharmaceutical company, announced that Remdantry™ will be available in Canada as of April 1, 2025. Remdantry™, previously ...